<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260521069470N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-06-14</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Comparing two drug adjuvants (dexmedetomidine and sufentanil) in epidural pain-free labour</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of adding dexmedetomidine and sufentanil to ropivacaine in patients who are candidates for epidural painless labour</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-06-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>204</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/90296</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Diagnostic, Randomization description: In this study, a permuted block randomization method will be used to allocate participants into two equal groups. Prior to the commencement of the study, a randomization sequence will be generated using statistical software (R or SPSS) based on balanced blocks of four. The possible permutations within each block include AABB, ABAB, BABA, BBAA, ABBA, and BAAB, where A denotes Group I (ropivacaine + sufentanil) and B denotes Group II (ropivacaine + dexmedetomidine). The generated randomization sequence will be placed in sequentially numbered, sealed, and opaque envelopes, which will be prepared and securely maintained by an independent person not involved in the study execution or data collection. Following confirmation of eligibility criteria and obtainment of written informed consent from each participant, the corresponding envelope will be opened in sequential order and the participant will be allocated to the designated group. Study medications will be prepared by an independent anesthesiologist who is aware of the randomization sequence; both drug combinations will be drawn into identical, unlabeled syringes of the same appearance and volume, ensuring that the patient, the administering anesthesiologist, and the data recorder remain blinded to group assignment throughout the entire study period, thereby maintaining a rigorous double-blind design, Blinding description: Drugs prepared in advance by the anaesthesia technician, labelled A/B in identical 10 mL syringes of the same appearance and colour
Patient, administering anaesthesiologist, and data-recording intern (triple-blind in practice).</study_design>
      <phase>3</phase>
      <hc_freetext>Labour pain / Epidural analgesia for labour.</hc_freetext>
      <i_freetext>Intervention 1: Epidural injection of 10 cc of 0.1% ropivacaine solution and 20 micrograms of sufentanil in the L2/L3 or L4/L5 intervertebral space in the active phase of labor (dilation greater than 4 cm). Sufentanil will be obtained from Abu Raihan Company and dexmedetomide from Eksir Pharmaceuticals. Intervention 2: Epidural injection of 10 cc of 0.1% ropivacaine solution and 0.1 micrograms/kilogram of dexmedetomidine in the L2/L3 or L4/L5 intervertebral space in the active phase of labor (dilation greater than 4 cm) and sufentanil from Abu Raihan Company and dexmedetomidine: Eksir Pharmaceuticals.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It is not yet known if there will be a plan to make this available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>saba khalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar Azam Complex, Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176341</zip>
        <telephone>+98 86 3417 3505</telephone>
        <email>m.ahmadlou11@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>saba khalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar Azam Complex, Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176341</zip>
        <telephone>+98 86 3417 3505</telephone>
        <email>m.ahmadlou11@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women candidates for painless delivery referred to Sina Rezaei Ashtiani Hospital, Arak
Nulliparous women (first delivery)
Singleton pregnancy
Use of ropivacaine as the base local anaesthetic
No known allergy to ropivacaine, dexmedetomidine, or sufentanil
Written informed consent
No contraindication to epidural anaesthesia</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Known hypersensitivity or allergy to ropivacaine, dexmedetomidine, or sufentanil
Presence of absolute or relative contraindications to epidural anesthesia (including coagulation disorders, local infection at injection site, or raised intracranial pressure)
Multiple gestation (twins or higher)
Multiparous women (previous vaginal delivery or cesarean section)
Non-vertex fetal presentation
Uncontrolled systemic diseases (uncontrolled diabetes mellitus, severe preeclampsia, significant cardiac disease)
Severe psychiatric disorders or opioid/substance dependence
Inability to provide written informed consent
Cervical dilation greater than 8 cm at time of presentation (advanced active phase)
Prior lumbar spinal surgery precluding successful epidural placement</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of spinal and epidural anesthesia during labor and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Diagnosis</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Epidural injection of 10 cc of 0.1% ropivacaine solution and 20 micrograms of sufentanil in the L2/L3 or L4/L5 intervertebral space in the active phase of labor (dilation greater than 4 cm). Sufentanil will be obtained from Abu Raihan Company and dexmedetomide from Eksir Pharmaceuticals</i_keyword>
      <i_keyword>Epidural injection of 10 cc of 0.1% ropivacaine solution and 0.1 micrograms/kilogram of dexmedetomidine in the L2/L3 or L4/L5 intervertebral space in the active phase of labor (dilation greater than 4 cm) and sufentanil from Abu Raihan Company and dexmedetomidine: Eksir Pharmaceuticals</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Labour pain intensity. Timepoint: Before intervention and at 5, 15, 30, and 60 min after epidural catheter placement. Method of measurement: Visual Analogue Scale (VAS) 0–10.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of analgesia. Timepoint: From onset of analgesia to first supplemental analgesia request or end of delivery. Method of measurement: Recorded in minutes by the assigned intern.</sec_outcome>
      <sec_outcome>Neonatal Apgar score at 1 and 5 minutes. Timepoint: At 1 and 5 minutes post-delivery. Method of measurement: Apgar scoring (0–10) by attending midwife or physician.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-05-16</approval_date>
        <contact_name>Ethics Committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Payambar Azam Complex, Sardasht Town Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
